Effects of Long-Term Use of Raloxifene, a Selective Estrogen Receptor Modulator, on Thyroid Function Test
Profiles, Sandy H.-J. Hsu, 1 Wern-Cherng Cheng, 1 Men-Wang Jang, 2 and Keh-Sung Tsai Estrogen (1) (2) (3) (4) (5) may increase hepatic production of thyroxine-binding globulin (TBG) and decrease TBG clearance (6 ) , thus increasing serum total thyroxine (tT 4 ) (3, 4 ) and, to a lesser extent, total triiodothyronine (tT 3 ) (3, 4 ) . As a result, increased tT 4 and tT 3 are seen in states of excessive estrogen and/or progestin, such as pregnancy, estrogen replacement therapy (HRT) (5 ) , and oral contraceptive usage (1 ) . This phenomenon may cause problems in clinical diagnoses when tT 4 or tT 3 is used for these patients. On the other hand, estrogen has been shown to increase thyroid-stimulating hormone (TSH) and to decrease free thyroxine (fT 4 ) through a mild inhibitory effect on the thyroid gland (4 ) . Compound that are analogs of estrogens, such as tamoxifen, have been shown to increase TSH without decreasing fT 4 (7, 8 ) . Recently, a new category of therapeutic agents, collectively termed selective estrogen receptor modulators (SERMs), has been developed to treat patients with postmenopausal osteoporosis (9 ) . Raloxifene is one SERM. It decreases bone resorption (9, 10 ) and serum LDL-cholesterol (9, 11, 12 ) , but it does not stimulate breast (13 ) or endometrium (14 ) at the recommended dosage of 60 mg daily. This agent is becoming one of the first-line pharmaceutical agents for postmenopausal osteoporosis and is currently administered to a large number of patients. However, the effect of long-term raloxifene usage on TBG, T 3 uptake, tT 3 , tT 4 , fT 4 , and TSH has not been well documented. To investigate whether raloxifene causes changes in serum concentrations of these markers, we compared the effects of 1 year of treatment with either raloxifene or combined continuous estrogen and progesterone (CCEP) on the thyroid function test profiles, estradiol 2 (E2), and folliclestimulating hormone (FSH).
We studied 60 euthyroid postmenopausal women (age range, 40 -75 years) with relatively low bone mineral density. The t-score, using the mean and SD of healthy premenopausal Taiwanese women as reference (15 ) , ranged from ϩ1 to Ϫ2.49. These 60 women were divided into two groups in a double-blind, randomized fashion.
Fifty women received raloxifene (60 mg daily) before breakfast, and 10 women received combined conjugated equine estrogen (premarin ® ; 0.625 mg) and medroxyprogesterone acetate (provera ® ; 5 mg) daily. Fasting serum samples were collected for all participants at baseline and after 1 year of treatment. All of the serum samples were stored at Ϫ70°C, thawed simultaneously, and measured on the same day. All participants completed the treatment program. The compliance was good for both groups. Pill counting showed that each patient consumed 85-100% of the tablets/capsules. Serum tT 3 , tT 4 , fT 4 , TBG, third-generation TSH, T 3 uptake, E2, and FSH were all measured using commercial chemiluminescent immunoassays and instruments (Immulite; DPC). The within-day imprecision (CVs) of these assays was 3-7%.
We used two-way ANOVA for repeated measures to compare the concentrations of E 2 and FSH and the thyroid function profiles between the two therapeutic groups, before and after treatment. The data were analyzed by the general linear model procedure (PROG GLM) included in the SAS package (SAS, Ver. 6.12; SAS Institute).
The anthropometric data and the mean value (Ϯ SE) for each thyroid function test item before and after treatment in the CCEP and raloxifene groups are shown in Table 1 . At baseline, there was no significant difference in height, weight, age, years since menopause, or thyroid function test items between these two groups. CCEP significantly increased serum TBG (17%), tT 3 (5.7%), and tT 4 (19%) and decreased T 3 uptake (9%), whereas it did not change TSH. The mean fT 4 concentration decreased by 3%, but the change was not statistically significant. Raloxifene also increased serum TBG (7.8%), tT 3 (4.4%), and tT 4 (5.7%) and decreased T 3 uptake (3.7%). The mean fT 4 concentration decreased by 3%, but this change was not statistically significant ( Table 1 ). The changes in these five markers were apparently smaller than those caused by CCEP but did not reach statistical significance.
Raloxifene did not change serum concentrations of HDL-cholesterol (12 ) or C-reactive protein (16 ) . On the contrary, CCEP increases the serum concentrations of C-reactive protein (16 ) and HDL-cholesterol (12 ) . Thus, SERMs such as raloxifene may have different effects on certain serum proteins compared with estrogen. In this study, we showed that the usual dosage of raloxifene administered for 1 year increased serum TBG. This increase in TBG is similar to the effects of CCEP and may then be associated with an increase of tT 4 and tT 3 , whereas TSH and fT 4 were not significantly changed. The slight but insignificant decreases in fT 4 in both groups after 1 year of treatment were compatible with the findings that showed a mild suppression of thyroid function by tamoxifen (7 ) and estrogen (4 ). Our findings indicated that in patients treated with raloxifene, the results of tT 3 and tT 4 tests should be interpreted with caution because they could be falsely increased. Until recently, the focus of our research in the noninvasive diagnosis of Down syndrome was the genetic analysis of intact fetal nucleated erythrocytes from the circulation of pregnant women (1 ) . The initial step in the physical isolation of these target cells involves the layering of diluted maternal blood on a density gradient (2 ) . Before 1997, we routinely discarded the plasma layer of the density gradient, unaware of the fact that it could contain nucleic acids. In 1997, prompted by reports of large quantities of tumor-specific DNA sequences in the plasma and serum of cancer patients (3) (4) (5) , Lo et al. (6 ) demonstrated the presence of male fetal DNA sequences in the serum and plasma of pregnant women. Subsequently, this same group extended their observations by quantifying the fetal DNA in maternal plasma (7 ) and studying its kinetics and physiology (8 ) .
The detection and/or quantification of fetal DNA sequences in maternal plasma have been used for a variety of clinical applications, including diagnosis of gender, Rhesus D genotype, single gene disorders, aneuploidy, and preeclampsia [reviewed in Refs. (9, 10 ) ]. More recently, it has also been suggested that the genetic material in the plasma consists of a continuum of intact and apoptotic cells as well as cell-free DNA (11, 12 ) . Fetal DNA, however, appears to exist predominantly in a cell-free form in the maternal plasma (13 ) . Despite advances in the clinical applications of this technology, to date not much is known about the tissue of origin of the cell-free fetal DNA and how it is metabolized in the pregnant woman.
Botezatu et al. (14 ) demonstrated that male DNA sequences could be found in the urine of women who received a blood transfusion from a male donor, as well as women who were pregnant with a male fetus. The mechanism of DNA transfer across the kidney was unknown. Other groups have not yet replicated these findings in the literature.
To understand the metabolism of fetal DNA in the mother, we decided to examine amniotic fluid because at 16 -20 weeks of gestation it is in transition from being identical to fetal plasma to being composed of fetal urine (15 ) . We hypothesized that demonstration of the existence of cell-free fetal DNA in amniotic fluid might provide a clue to the tissue source of DNA in the maternal plasma, as well as lead to novel clinical applications.
This study was performed with approval from the hospital's Institutional Review Board. Thirty-eight coded frozen discarded amniotic fluid specimens were obtained from the Cytogenetics Laboratory. All samples were collected for routine indications, such as advanced maternal age, abnormal maternal serum screening results, or detection of a fetal sonographic abnormality. The standard protocol in the Cytogenetics Laboratory is, upon receipt, to centrifuge the amniotic fluid sample at 350g for 10 min in a bench-top centrifuge, place the cell pellet in tissue culture, assay an aliquot of the fluid for ␣-fetoprotein and acetyl cholinesterase, and store the remainder at Ϫ20°C as a back-up in case of assay failure. After 6 months, the frozen amniotic fluid supernatant samples usually are discarded. Results of the fetal karyotype were revealed only after the study was completed.
The frozen amniotic fluid samples were initially thawed at 37°C and then vortex-mixed for 15 s. An aliquot of 500 L of fluid was centrifuged at 13 500g in a microcentrifuge to remove any remaining cells. A final volume of 400 L of the supernatant was used for extraction of DNA. Extraction was performed with the QIAamp Blood Kit (Qiagen) using the "Blood and Body Fluid" protocol as described by the manufacturer. The DNA was eluted into a final volume of 100 L. Aerosol-resistant tips were used throughout the protocol to prevent contamination with exogenous DNA.
Real-time quantitative PCR analysis was performed using a Perkin-Elmer Applied Biosystems (PE-ABI) 7700 Sequence Detector. Analysis was based on the 5Ј-to-3Ј exonuclease
